Skip to main content

Nutritional Screening Tools

The 2024 NEJM review recommends screening for malnutrition within the first 24–48 hours of admission to a hospital or nursing home, using any validated tool that classifies persons as at risk or malnourished based on two or three criteria.[1] For hospitalized adults, NRS-2002, MUST, SNAQ, and MST all provide rapid assessment; the MNA-SF is adapted for older adults; the NUTRIC / mNUTRIC score is the only tool designed for the ICU.[1]

Critically, screening is not diagnosis. The GLIM criteria provide the standardized two-step diagnostic process — screen with a validated tool, then confirm malnutrition diagnosis by combining ≥ 1 phenotypic and ≥ 1 etiologic criterion.[1][15]

For the reconstructive urologist and urogynecologist, the high-yield framework: MUST as the surgical workhorse (highest validated combined diagnostic + prognostic accuracy in a 2025 multicenter surgical cohort), MNA-SF for older urogyn / cystectomy patients, mNUTRIC for ICU stays after major reconstruction, and GLIM as the formal diagnostic step once a screen is positive. The traditional serum biomarkers (albumin, prealbumin, transferrin) should not be used as nutritional status markers per ACG — they are markers of inflammation and risk.

Detailed Overview of Individual Screening Tools​

Malnutrition Screening Tool (MST)​

The simplest validated screening tool — only 2 questions assessing recent weight loss and appetite. A score ≥ 2 (maximum 7) triggers referral for comprehensive nutritional assessment.[2][3] The Academy of Nutrition and Dietetics (AND) position statement recommends the MST as the single preferred tool for screening adults for malnutrition regardless of age, medical history, or setting, based on Grade I (good / strong) evidence.[4][5] Original validation reported sensitivity and specificity both at 93% against SGA, though subsequent studies have shown more variable sensitivity (42–74%).[3]

Malnutrition Universal Screening Tool (MUST)​

Developed by BAPEN, MUST evaluates 3 parameters:[2][3]

  • BMI — 0 points (> 20), 1 point (18.5–20), 2 points (< 18.5)
  • Unintentional weight loss in past 3–6 months — 0 (< 5%), 1 (5–10%), 2 (> 10%)
  • Acute disease effect (no nutritional intake likely for > 5 days) — 0 (absent), 2 (present)

Total score: 0 = low risk, 1 = medium risk, ≥ 2 = high risk. Administration takes < 5 minutes.[3]

A 2024 meta-analysis found MUST had the highest overall accuracy among screening tools validated against SGA (sensitivity 84%, specificity 85%) and ESPEN criteria (sensitivity 97%, specificity 80%).[6] A 2025 multicenter surgical study (1,649 patients) confirmed MUST as the most valid screening tool for major abdominal surgery patients, with both sensitivity and specificity close to 80% and the best combined diagnostic and prognostic validity.[7] When paired with GLIM criteria, MUST demonstrated the highest accuracy (86.8%) and was an independent predictor of worse clinical outcomes.[8]

Nutritional Risk Screening 2002 (NRS-2002)​

Recommended by ESPEN for hospitalized patients, NRS-2002 uses a two-phase approach:[2][3]

  • Initial screening (4 yes/no questions) — BMI < 20.5, weight loss in 3 months, reduced intake in past week, severely ill.
  • Final screening — Nutritional status score (0–3) + disease severity score (0–3) + age adjustment (+1 if ≥ 70).
  • Total ≥ 3 = at nutritional risk.

In patients with NRS-2002 scores ≥ 5, receipt of sufficient nutrition therapy was associated with a 50% reduction in nosocomial infection and total complications; in patients with scores ≤ 3, nutrition therapy did not alter outcomes regardless of amount delivered.[9] NRS-2002 also has proven prognostic value for long-term mortality, particularly in polymorbid patients.[3]

Mini Nutritional Assessment — Short Form (MNA-SF)​

Designed specifically for older adults (≥ 65 years), the MNA-SF consists of 6 questions assessing:[10][2]

  1. Decreased food intake (0–2 points).
  2. Weight loss in past 3 months (0–3 points).
  3. Mobility (0–2 points).
  4. Acute illness or psychological stress (0–2 points).
  5. Neuropsychological problems (0–2 points).
  6. BMI or calf circumference (0–3 points).

Total score (0–14): 12–14 = normal, 8–11 = at risk, 0–7 = malnourished. The 2025 NEJM review on malnutrition in older adults identifies the MNA-SF as the best-validated screening tool for this population, noting that a score ≤ 11 indicates risk.[10] The MNA-SF has high sensitivity (94–99%) but lower specificity (39–60%) — captures most at-risk patients but may over-refer.[2] Administration takes < 5 minutes.[2]

Short Nutritional Assessment Questionnaire (SNAQ)​

Three questions: unintentional weight loss (> 3 kg in past month or > 6 kg in past 6 months), decreased appetite in past month, and use of supplemental drinks or tube feeding. Maximum score is 5, with categories for well-nourished, moderately malnourished, and severely malnourished, each linked to a specific care plan.[11] High specificity but lower sensitivity compared to MUST and NRS-2002.[2]

Assessment and Diagnostic Tools​

Subjective Global Assessment (SGA)​

The SGA is the most widely used reference standard for nutritional assessment and the comparator against which most screening tools are validated.[2][12][13] It evaluates:

  • History — Weight change, dietary intake change, GI symptoms (> 2 weeks), functional capacity changes.
  • Physical examination — Loss of subcutaneous fat, muscle wasting, ankle / sacral edema, ascites.

Patients are classified as:

  • SGA-A — Well-nourished.
  • SGA-B — Moderately malnourished (5–10% weight loss, reduced intake, loss of subcutaneous tissue).
  • SGA-C — Severely malnourished (> 10% weight loss, severe muscle / fat loss, or edema).[2]

The SGA requires trained clinicians and takes longer than screening tools but reliably predicts morbidity and mortality.[12][13] The AND/ASPEN malnutrition-diagnosis criteria derive from the SGA framework.[13]

Patient-Generated Subjective Global Assessment (PG-SGA)​

An oncology adaptation of the SGA. Patient-completed sections (weight history, food intake, symptoms, activities) plus professional-completed sections (disease, metabolic demand, physical examination). The scored version provides a numerical score: ≥ 9 indicates critical need for nutrition intervention.[11] ASPEN recommends the PG-SGA Short Form for oncology outpatient screening.[11]

GLIM Criteria — The Diagnostic Framework​

The GLIM criteria represent the current international consensus for diagnosing (not screening for) malnutrition, endorsed by ESPEN, ASPEN, the Latin American Federation of Nutritional Therapy, and the Parenteral and Enteral Nutrition Society of Asia.[14]

Step 1 — Screen with any validated tool (MST, MUST, NRS-2002, MNA-SF, etc.).

Step 2 — Diagnose by confirming ≥ 1 phenotypic + ≥ 1 etiologic criterion:[1][2][14]

Phenotypic (any 1)Etiologic (any 1)
Unintentional weight loss > 5% in < 6 months, or > 10% in > 6 monthsDecreased food intake / assimilation (< 50% of energy requirements > 1 week, any reduction > 2 weeks, or chronic GI malabsorption)
Low BMI (< 20 kg/m² if age < 70; < 22 if ≥ 70)Inflammation / disease burden (acute or chronic)
Reduced muscle mass—

Severity grading: Moderate vs severe based on degree of phenotypic aberration.[14] A comparison study found that NRS-2002 screening missed 37 of 114 GLIM-diagnosed malnourished patients, primarily those with inflammation and reduced muscle mass not captured by the screening tool — highlighting that screening and GLIM diagnosis are complementary, not interchangeable.[15]

Because technical devices for measuring body composition are not usually available, calf circumference and trained physical examination are GLIM-approved methods for estimating muscle mass.[1]

ICU-Specific: NUTRIC Score​

The Nutrition Risk in the Critically Ill (NUTRIC) score is the only tool specifically designed for ICU patients, incorporating both nutritional status and disease severity.[16][17] The modified NUTRIC (mNUTRIC, without IL-6) includes:

  • Age, APACHE II (or SAPS 3), SOFA score, number of comorbidities, days from hospital to ICU admission, and number of days of mechanical ventilation.

A score ≥ 5 identifies high nutritional risk.[16] In the SCCM/ASPEN 2016 guidelines, patients with high NUTRIC scores (6–10) showed significant decreases in mortality the closer nutrition delivery was to goal, whereas patients with low scores (0–5) showed no association.[9] mNUTRIC has demonstrated fair-to-good discrimination for 28-day mortality (AUC 0.77–0.81).[18][17] A 2025 study combining mNUTRIC + GLIM into a novel 4-group classification showed the strongest prognostic performance for in-hospital mortality (AUC 0.76), outperforming validated severity scoring systems alone.[19]

Sarcopenia-Specific: SARC-F​

The SARC-F is a 5-item self-administered questionnaire recommended by EWGSOP2 for sarcopenia case-finding:[20][21]

  • Strength (difficulty lifting / carrying 10 lbs)
  • Assistance in walking
  • Rise from a chair
  • Climb stairs
  • Falls

Each item scored 0–2 (total 0–10); ≥ 4 suggests probable sarcopenia. SARC-F has high specificity but low-to-moderate sensitivity (33–50%) — better at ruling out than detecting.[20][22] A 2026 study suggested lowering the cutoff to ≥ 2 may improve early detection in community-dwelling older adults (AUC 0.70–0.74 for HGS and sit-to-stand tests).[23]

Comparative Validity Summary​

ToolSettingComponentsTimeSensitivitySpecificityKey advantage
MSTAll settings, all adultsWeight loss, appetite (2 questions)2 min81% (vs SGA)79%Simplest; AND-recommended for all adults
MUSTHospital, communityBMI, weight loss, acute disease (3 items)2 min84% (vs SGA)85%Highest overall accuracy; predicts LOS, readmission
NRS-2002Hospital (ESPEN)Nutritional status + disease severity + age2–3 min76% (vs SGA)86%Identifies patients who benefit from nutrition therapy
MNA-SFOlder adults (≥ 65)6 questions (intake, weight, mobility, stress, neuro, BMI)5 min94–99%39–60%Best validated for geriatric populations
SNAQHospitalWeight loss, appetite, supplements (3 questions)2 min70–78%65–68%Linked to specific care plans
SGAAll settings (assessment)History + physical exam10–15 minReference standardReference standardGold standard for diagnosis; predicts morbidity / mortality
NUTRIC / mNUTRICICUAge, APACHE II, SOFA, comorbidities, hospital days5 minPrognosticPrognosticOnly ICU-specific tool; identifies who benefits from feeding
SARC-FCommunity, hospitalStrength, walking, rising, stairs, falls (5 items)2 min33–50%~ 85%Self-administered; high specificity for sarcopenia

Choosing the Right Tool by Setting​

The traditional serum biomarkers (albumin, prealbumin, transferrin) should not be used as nutritional status markers — ACG explicitly recommends against this, instead recognizing them as surrogate markers of inflammation and risk.[9] Choose the screening tool by setting:

  • All adults, any setting — MST (AND recommendation).[4]
  • Hospitalized adults — MUST or NRS-2002 (ESPEN); MUST may be preferred as the first step in the GLIM approach based on highest accuracy.[8][7]
  • Older adults (≥ 65) — MNA-SF (best validated).[10]
  • ICU patients — mNUTRIC (SCCM/ASPEN recommendation).[16]
  • Oncology outpatients — PG-SGA Short Form or MST (ASPEN recommendation).[11]
  • Surgical patients — MUST (best combined diagnostic and prognostic validity in a 1,649-patient multicenter study).[7]
  • Sarcopenia screening — SARC-F (EWGSOP2), complemented by handgrip strength.[20]

Reconstructive Relevance​

1. The Surgical Default — MUST as the First-Line Tool​

For any major elective reconstruction (radical cystectomy + diversion, complex prolapse repair, gender-affirming phalloplasty / vaginoplasty, BMG urethroplasty, posterior PFUI urethroplasty, exenteration revision), MUST is the validated first-line screen:

  • Takes < 5 minutes.
  • Petra 2025 multicenter prospective study (n = 1,649 surgical patients) confirmed MUST as the most valid screening tool for major abdominal surgery, with the best combined diagnostic and prognostic validity.
  • 86.8% accuracy when paired with GLIM diagnostic confirmation.
  • Independently predicts worse postoperative outcomes.

Integrate MUST into the preoperative clinic intake for all major reconstruction. A positive MUST (≥ 1) should trigger:

  • Formal GLIM diagnosis with body-composition assessment (CT-SMI on staging scans, DXA, BIA, or calf-circumference surrogate).
  • Handgrip strength for functional sarcopenia confirmation.
  • CRP for the GLIM etiologic criterion (inflammation).
  • Nutritional therapy + prehabilitation referral; consider deferring elective reconstruction.

2. Geriatric Reconstructive Populations — MNA-SF​

For patients ≥ 65 years undergoing reconstruction — the typical age band for radical cystectomy, complex prolapse repair, and many BMG urethroplasties — MNA-SF is the geriatric-validated workhorse:

  • 6 questions, < 5 minutes.
  • AUC 0.83 in older surgical populations.
  • High sensitivity (94–99%) — captures most at-risk patients.
  • Lower specificity (39–60%) — over-refers, which is the right error direction in this population.
  • Integrates BMI or calf circumference as the 6th item — making it the most age-appropriate screen for sarcopenic older patients.

3. ICU Stays After Major Reconstruction — mNUTRIC​

For the patient in ICU after radical cystectomy + diversion, exenteration, major trauma reconstruction, or complications from any major surgery:

  • mNUTRIC ≥ 5 identifies high nutritional risk.
  • Patients with high NUTRIC scores (6–10) show significant mortality reduction with goal-directed nutrition delivery; low-score patients do not benefit from aggressive nutrition.
  • mNUTRIC + GLIM combined 4-group classification (Kim 2025) achieved AUC 0.76 for in-hospital mortality, outperforming severity scores alone.
  • Standard SCCM/ASPEN ICU nutrition framework.

4. Oncology Reconstruction — PG-SGA Short Form​

For cancer-survivorship reconstruction (post-cystectomy revision, post-exenteration neovagina, post-radiation fistula repair, post-prostatectomy AUS / sling, GAS in cancer survivors):

  • PG-SGA Short Form is the ASPEN-recommended oncology screen.
  • Scored version: ≥ 9 = critical need for intervention before elective reconstruction.
  • Combines patient-reported symptoms and intake with clinician-assessed disease burden.

5. The Screening-vs-Diagnosis Distinction​

Screening tools (MUST, NRS-2002, MNA-SF, MST, SARC-F) identify risk. GLIM diagnoses malnutrition. This matters because:

  • A positive screen alone does not document malnutrition for billing, prehab referral, or formal preoperative deferral.
  • GLIM requires both a phenotypic and an etiologic criterion — without confirming both, you have suspicion, not diagnosis.
  • NRS-2002 missed 37/114 GLIM-diagnosed malnourished patients in one comparison — particularly those with inflammation-driven sarcopenia. Always pair the screen with GLIM confirmation in surgical populations where you'll act on the result.
  • Calf circumference is GLIM-endorsed as a bedside surrogate for reduced muscle mass when DXA / BIA / CT is unavailable.

6. The Serum-Biomarker Rule​

Do NOT use serum albumin, prealbumin, or transferrin as a nutritional-status diagnosis. Per ACG / ASPEN 2021, they are markers of inflammation and nutritional risk, not malnutrition. See Serum Albumin and Prealbumin for the full ASPEN paradigm shift.

See Also​

References​

1. Cederholm T, Bosaeus I. "Malnutrition in Adults." The New England Journal of Medicine. 2024;391(2):155–165. doi:10.1056/NEJMra2212159

2. Cortes R, Yañez AM, Capitán-Moyano L, Millán-Pons A, Bennasar-Veny M. "Evaluation of different screening tools for detection of malnutrition in hospitalised patients." Journal of Clinical Nursing. 2024;33(12):4759–4771. doi:10.1111/jocn.17170

3. Chrástecká M, Blanař V, Pospíchal J. "Risk of malnutrition assessment in hospitalised adults: A scoping review of existing instruments." Journal of Clinical Nursing. 2023;32(13–14):3397–3411. doi:10.1111/jocn.16470

4. Skipper A, Coltman A, Tomesko J, et al. "Reprint of: Position of the Academy of Nutrition and Dietetics: Malnutrition (Undernutrition) Screening Tools for All Adults." Journal of the Academy of Nutrition and Dietetics. 2022;122(10S):S50–S54. doi:10.1016/j.jand.2022.07.013

5. Skipper A, Coltman A, Tomesko J, et al. "Position of the Academy of Nutrition and Dietetics: Malnutrition (Undernutrition) Screening Tools for All Adults." Journal of the Academy of Nutrition and Dietetics. 2020;120(4):709–713. doi:10.1016/j.jand.2019.09.011

6. Cortés-Aguilar R, Malih N, Abbate M, et al. "Validity of Nutrition Screening Tools for Risk of Malnutrition Among Hospitalized Adult Patients: A Systematic Review and Meta-Analysis." Clinical Nutrition. 2024;43(5):1094–1116. doi:10.1016/j.clnu.2024.03.008

7. Petra G, Kritsotakis EI, Gouvas N, et al. "Multicentre Prospective Study on the Diagnostic and Prognostic Validity of Malnutrition Assessment Tools in Surgery." The British Journal of Surgery. 2025;112(2):znaf013. doi:10.1093/bjs/znaf013

8. Lima J, Brizola Dias AJ, Burgel CF, et al. "Complementarity of Nutritional Screening Tools to GLIM Criteria on Malnutrition Diagnosis in Hospitalised Patients: A Secondary Analysis of a Longitudinal Study." Clinical Nutrition. 2022;41(10):2325–2332. doi:10.1016/j.clnu.2022.08.022

9. McClave SA, DiBaise JK, Mullin GE, Martindale RG. "ACG Clinical Guideline: Nutrition Therapy in the Adult Hospitalized Patient." The American Journal of Gastroenterology. 2016;111(3):315–334. doi:10.1038/ajg.2016.28

10. Cruz-Jentoft AJ, Volkert D. "Malnutrition in Older Adults." The New England Journal of Medicine. 2025;392(22):2244–2255. doi:10.1056/NEJMra2412275

11. Trujillo EB, Kadakia KC, Thomson C, et al. "Malnutrition Risk Screening in Adult Oncology Outpatients: An ASPEN Systematic Review and Clinical Recommendations." JPEN. Journal of Parenteral and Enteral Nutrition. 2024;48(8):874–894. doi:10.1002/jpen.2688

12. Duerksen DR, Laporte M, Jeejeebhoy K. "Evaluation of Nutrition Status Using the Subjective Global Assessment: Malnutrition, Cachexia, and Sarcopenia." Nutrition in Clinical Practice. 2021;36(5):942–956. doi:10.1002/ncp.10613

13. Hummell AC, Cummings M. "Role of the Nutrition-Focused Physical Examination in Identifying Malnutrition and Its Effectiveness." Nutrition in Clinical Practice. 2022;37(1):41–49. doi:10.1002/ncp.10797

14. Jensen GL, Cederholm T, Correia MITD, et al. "GLIM Criteria for the Diagnosis of Malnutrition: A Consensus Report From the Global Clinical Nutrition Community." JPEN. Journal of Parenteral and Enteral Nutrition. 2019;43(1):32–40. doi:10.1002/jpen.1440

15. Trollebø MA, Skeie E, Revheim I, et al. "Comparison of Nutritional Risk Screening With NRS2002 and the GLIM Diagnostic Criteria for Malnutrition in Hospitalized Patients." Scientific Reports. 2022;12(1):19743. doi:10.1038/s41598-022-23878-3

16. McClave SA, Taylor BE, Martindale RG, et al. "Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: SCCM and ASPEN." JPEN. Journal of Parenteral and Enteral Nutrition. 2016;40(2):159–211. doi:10.1177/0148607115621863

17. Duran HT, Kilinç OÖ. "Predictive Value of the mNUTRIC Score and Survival Analysis in Critically-Ill Patients Hospitalized in the Intensive Care Unit: A Prospective Observational Study." Medicine. 2025;104(44):e45645. doi:10.1097/MD.0000000000045645

18. Souza IAO, Ribeiro PC, Jonckheer J, De Waele E, Taniguchi LU. "Performance of NUTRIC Score to Predict 28-Day Mortality in Critically Ill Patients After Replacing APACHE II With SAPS 3." PLoS One. 2022;17(7):e0270455. doi:10.1371/journal.pone.0270455

19. Kim HJ, Shim JC, Oh JH, et al. "A Novel Nutritional Assessment Tool Combining the mNUTRIC Score and the GLIM Criteria With Prognostic Value for in-Hospital Mortality in Critically Ill Patients: A Single-Center Retrospective Cohort Study." The American Journal of Clinical Nutrition. 2025;122(1):306–314. doi:10.1016/j.ajcnut.2025.05.005

20. Cruz-Jentoft AJ, Sayer AA. "Sarcopenia." Lancet. 2019;393(10191):2636–2646. doi:10.1016/S0140-6736(19)31138-9

21. Bahat G, Erdoğan T, İlhan B. "SARC-F and Other Screening Tests for Sarcopenia." Current Opinion in Clinical Nutrition and Metabolic Care. 2022;25(1):37–42. doi:10.1097/MCO.0000000000000801

22. Krzymińska-Siemaszko R, Deskur-Śmielecka E, Kaluźniak-Szymanowska A, Styszyński A, Wieczorowska-Tobis K. "Polish Version of SARC-F to Assess Sarcopenia in Older Adults: An Examination of Reliability and Validity." PLoS One. 2020;15(12):e0244001. doi:10.1371/journal.pone.0244001

23. Cengiz D, Baş AO, Öztürk Y, et al. "Optimising SARC-F Cut-Off for Sarcopenia Screening: A Comparative Analysis With Muscle Strength and Physical Performance Tests." Nutrition. 2026;146:113132. doi:10.1016/j.nut.2026.113132